Lopinavir/ritonavir population pharmacokinetics in neonates and infants. - Wikidata - wikimedia - TriplyDB

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

http://www.wikidata.org/entity/Q34996974

about

The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.Getting to 90-90-90 in paediatric HIV: What is needed?Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling.Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response.Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Developments in early diagnosis and therapy of HIV infection in newborns.Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations.Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.Antiretroviral therapy during the neonatal period.British HIV Association guidelines for the management of HIV infection in pregnant women 2012

P2860

Q30382184-95991A28-2E72-4B2F-BFC0-6EBC362E1797 Q30385352-F5871B8B-FA97-4165-B590-662A721B8E6A Q30832465-FF09B24C-D4B3-4DBC-832B-3502089E74BC Q30938796-6695B419-8642-40E6-B2AF-492CF80F0450 Q33887993-2EB2C06D-B8F9-4759-8CB2-8FE4EF9E603E Q36887756-7BAA606F-A037-47EA-9BA7-34131FA7B5C5 Q38325427-7C548F8F-5EAA-48E3-9454-87650BAC5AE5 Q38648601-510AAA12-281A-42F3-AF91-54C42684415D Q45932455-8A2983D8-7029-4CCB-9639-469A8B8B42A0 Q46895816-24A48ED4-33FC-4A58-9B59-C2BFC7B6347A Q53801515-9FC496AF-5C27-4280-A11F-957C432A3403 Q57076282-9DB3B09E-7A28-48C6-AD8A-A7240638CCC6

P2860

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

http://www.wikidata.org/entity/Q34996974

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@ast

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@en

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@nl

type

label

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@ast

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@en

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@nl

prefLabel

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@ast

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@en

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@nl

P1433

Q34996974-9D56106F-6753-4EEC-84B1-03DE7B8BB093

P1476

Q34996974-915E3D29-1D62-4AD4-80F2-AD7A8891DCB1

P2093

Q34996974-2A2C4E53-F28E-482A-9A38-D363152888D3

Q34996974-3E7047A8-AFF8-4A85-8F70-02DB22094B54

Q34996974-533C6D88-2049-490A-9FC3-0C454CE12CC6

Q34996974-564F554D-868F-4DAD-855C-6073181288E2

Q34996974-5E9EB56E-29A7-4620-B4F5-8329B32E510F

Q34996974-60E1FB25-3A28-486D-9AC0-9B000F06A488

Q34996974-80119422-A2C7-4D6E-B44B-0239FB019AD2

Q34996974-8D85D98E-CBB7-4D49-BFFB-324A132F7AFA

Q34996974-A8261C12-8570-4FAD-8A1A-E54EF4189054

Q34996974-AB884509-E3D8-4D07-9DBA-5D308E1996EA

P2860

Q34996974-10D79A1A-5B20-423A-BB6C-F8BE1C821CFE

Q34996974-29B030FF-9B35-418D-A3A2-64A89C520CB2

Q34996974-3EAD09C0-CCD1-4734-8C99-178605FC3210

Q34996974-5B4A2A0C-2B9D-436F-83E0-ECFD8F1E7994

Q34996974-82201E86-D82E-43EB-9196-FD35815EFD4D

Q34996974-8ABFBFD8-7130-4ACD-9A9F-CDACDAABC414

Q34996974-C0108FFA-C679-4334-BEB6-E310D176009F

P304

Q34996974-4867B8A1-0246-41AF-93CD-4B7FE58B8A65

P31

Q34996974-06C8212A-BF0C-4F11-8EB3-560C7760B973

P356

Q34996974-9AE89549-4C2C-46F8-9ACE-8AF8D6258104

P407

Q34996974-925E24EC-E65E-40B1-BE18-CB542D185962

P433

Q34996974-91C20DF4-47C1-4862-9ABB-E86E74DD7A5E

P478

Q34996974-D2034C9E-D1D0-4443-89BE-41D3DD101E3C

P50

Q34996974-A6E1AA0A-8D53-46DD-8D1F-3F8C7849E199

Q34996974-C74857DD-ACBF-4168-A32B-FEB0C30EB29D

Q34996974-DAE8D9BF-4732-4BA7-83AA-34BE5B188953

P577

Q34996974-1615E8D3-CE8C-4325-A2B9-D45A9BB207FB

P5875

Q34996974-1FB6841F-C791-407D-A8CC-15818DD1278F

P698

Q34996974-1F229740-8C4A-437F-85E5-C5A0EF414B48

P932

Q34996974-CD2EF226-B7B7-49E4-B6FC-27B16AD8401E

P356

J.1365-2125.2011.03926.X

P1433

British Journal of Clinical Pharmacology

P1476

Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

@en

P2093

Albert Faye

http://www.w3.org/2001/XMLSchema#string

Carole Giraud

http://www.w3.org/2001/XMLSchema#string

Caroline Solas

http://www.w3.org/2001/XMLSchema#string

Deborah Hirt

http://www.w3.org/2001/XMLSchema#string

Ghislaine Firtion

http://www.w3.org/2001/XMLSchema#string

Hermione Lyall

http://www.w3.org/2001/XMLSchema#string

Isabelle Thuret

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Tréluyer

http://www.w3.org/2001/XMLSchema#string

Marthe Leprevost

http://www.w3.org/2001/XMLSchema#string

Saik Urien

http://www.w3.org/2001/XMLSchema#string

P2860

Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients

Mechanism-based concepts of size and maturity in pharmacokinetics.

Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.

R: A Language for Data Analysis and Graphics

P304

956-960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2011.03926.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Marc Tréluyer

Gilles Peytavin

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229961956

http://www.w3.org/2001/XMLSchema#string

P698

21564164

http://www.w3.org/2001/XMLSchema#string

P932

3099384

http://www.w3.org/2001/XMLSchema#string